Bristol Myers posts higher-than-expected quarterly profit on blood thinner, cancer sales

Bristol Myers Squibb reported first-quarter profit that beat Wall Street expectations, supported by stronger-than-expected growth in blood thinner Eliquis and newer cancer drugs. The result points to improving operating fundamentals and healthier product momentum across key franchises.

Analysis

Bristol Myers Squibb reported first-quarter profit that beat Wall Street expectations, supported by stronger-than-expected growth in blood thinner Eliquis and newer cancer drugs. The result points to improving operating fundamentals and healthier product momentum across key franchises.